Metalloproteinases in idiopathic pulmonary fibrosis

European Respiratory Journal

Volumn 38, Issue 6, 2011, Pages 1461-1467

  Dancer, R C A ^a   Wood, A M ^a   Thickett, D R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Idiopathic pulmonary fibrosis; Matrix metalloproteinase

Indexed keywords

AZATHIOPRINE; BLEOMYCIN; COLLAGEN; COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; PIRFENIDONE; PREDNISOLONE; STROMELYSIN;

ENZYME ACTIVITY; ENZYME REGULATION; FIBROSING ALVEOLITIS; HUMAN; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW;

ANIMALS; COLLAGEN; EXTRACELLULAR MATRIX; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MATRIX METALLOPROTEINASES; MICE; MICE, TRANSGENIC; RATS;

EID: 79960189227     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00024711     Document Type: Review

References (61)

1. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157: 1301-1315.
2. Cool CD, Groshong SD, Rai PR, et al. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med 2006; 174: 654-658. (Pubitemid 44395332)
3. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006; 3: 364-372. (Pubitemid 43845414)
4. Andersson-Sjoland A, de Alba CG, Nihlberg K, et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008; 40: 2129-2140.
5. Kinder BW, Brown KK, Schwarz MI, et al. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 2008; 133: 226-232.
6. Gunther A, Mosavi P, Ruppert C, et al. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost 2000; 83: 853-860. (Pubitemid 30411683)
7. Cosgrove GP, Brown KK, Schiemann WP, et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 2004; 170: 242-251. (Pubitemid 38971408)
8. Goh NS, Desai SR, Anagnostopoulos C, et al. Increased epithelial permeability in pulmonary fibrosis in relation to disease progression. Eur Respir J 2011; 38: 184-190.
9. McKeown S, Richter AG, O'Kane C, et al. MMP expression and abnormal lung permeability are important determinants of outcome in IPF. Eur Respir J 2009; 33: 77-84.
10. Pardo A, Selman M, Kaminski N. Approaching the degradome in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol 2008; 40: 1141-1155.
11. Madri JA, Furthmayr H. Collagen polymorphism in the lung. An immunochemical study of pulmonary fibrosis. Hum Pathol 1980; 11: 353-366. (Pubitemid 10032506)
12. Löffek S, Schilling O, Franzke C-W. Biological role of matrix metalloproteinases: a critical balance. Eur Respir J 2011; 38: 191-208.
13. Lammi L, Ryhanen L, Lakari E, et al. Type III and type I procollagen markers in fibrosing alveolitis. Am J Respir Crit Care Med 1999; 159: 818-823. (Pubitemid 29137779)
14. Raghu G, Striker LJ, Hudson LD, et al. Extracellular matrix in normal and fibrotic human lungs. Am Rev Respir Dis 1985; 131: 281-289. (Pubitemid 15167076)
15. Kaarteenaho-Wiik R, Lammi L, Lakari E, et al. Localization of precursor proteins and mRNA of type I and III collagens in usual interstitial pneumonia and sarcoidosis. JMol Histol 2005; 36: 437-446. (Pubitemid 43781457)
16. Gadek JE, Kelman JA, Fells G, et al. Collagenase in the lower respiratory tract of patients with idiopathic pulmonary fibrosis. N Engl J Med 1979; 301: 737-742. (Pubitemid 10250477)
17. Thickett DR, Poole AR, Millar AB. The balance between collagen synthesis and degradation in diffuse lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 27-33. (Pubitemid 32280534)
18. Selman M, Ruiz V, Cabrera S, et al. TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol 2000; 279: L562-L574.
19. Montano M, Ramos C, Gonzalez G, et al. Lung collagenase inhibitors and spontaneous and latent collagenase activity in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis. Chest 1989; 96: 1115-1119. (Pubitemid 19266570)
20. Ramos C, Montano M, Garcia-Alvarez J, et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 2001; 24: 591-598. (Pubitemid 32442767)
21. Zhou LF, Jiang L, Li ZH, et al. [Change of matrix metalloproteinase-1 and matrix metalloproteinase-7 in serum and bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and sarcoidosis]. Zhonghua Jie He He Hu Xi Za Zhi 2010; 33: 441-444.
22. Selman M, Pardo A, Barrera L, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006; 173: 188-198. (Pubitemid 43187891)
23. Konishi K, Gibson KF, Lindell KO, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 180: 167-175.
24. Yang IV, Burch LH, Steele MP, et al. Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med 2007; 175: 45-54. (Pubitemid 46105308)
25. Checa M, Ruiz V, Montano M, et al. MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. Hum Genet 2008; 124: 465-472.
26. Limb GA, Matter K, Murphy G, et al. Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am J Pathol 2005; 166: 1555-1563. (Pubitemid 40586523)
27. Fukuda Y, Ishizaki M, Kudoh S, et al. Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase- 2 in interstitial lung diseases. Lab Invest 1998; 78: 687-698. (Pubitemid 28307326)
28. Ruiz V, Ordonez RM, Berumen J, et al. Unbalanced collagenases/TIMP-1 expression and epithelial apoptosis in experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2003; 285: L1026-L1036. (Pubitemid 37310092)
29. O'Kane CM, McKeown SW, Perkins GD, et al. Salbutamol upregulates matrix metalloproteinase-9 in the alveolar space in the acute respiratory distress syndrome. Crit Care Med 2009; 37: 2242-2249.
30. Radisky DC, Levy DD, Littlepage LE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005; 436: 123-127. (Pubitemid 40966197)
31. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia 2010; 15: 201-212.
32. Uhal BD, Joshi I, Hughes WF, et al. Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am J Physiol 1998; 275: L1192-L1199.
33. Richter AG, McKeown S, Rathinam S, et al. Soluble endostatin is a novel inhibitor of epithelial repair in idiopathic pulmonary fibrosis. Thorax 2009; 64: 156-161.
34. Zuo F, Kaminski N, Eugui E, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002; 99: 6292-6297. (Pubitemid 34493305)
35. Kaminski N, Zuo F, Cojocaro G, et al. Use of oligonucleotide microarrays to analyse gene expression patterns in pulmonary fibrosis reveals distinct patterns of gene expression in mice and humans. Chest 2002; 121: 31S-32S. (Pubitemid 34248328)
36. Vuorinen K, Myllarniemi M, Lammi L, et al. Elevated matrilysin levels in bronchoalveolar lavage fluid do not distinguish idiopathic pulmonary fibrosis from other interstitial lung diseases. APMIS 2007; 115: 969-975. (Pubitemid 47256289)
37. Henry MT, McMahon K, Mackarel AJ, et al. Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF. Eur Respir J 2002; 20: 1220-1227. (Pubitemid 35331881)
38. Strieter RM, Keeley EC, Burdick MD, et al. The role of circulating mesenchymal progenitor cells, fibrocytes, in promoting pulmonary fibrosis. Trans Am Clin Climatol Assoc 2009; 120: 49-59.
39. Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 588-594.
40. Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 2003; 28: 12-24. (Pubitemid 36017046)
41. Lemjabbar H, Gosset P, Lechapt-Zalcman E, et al. Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis: effects of steroid and immunosuppressive treatment. Am J Respir Cell Mol Biol 1999; 20: 903-913. (Pubitemid 129540849)
42. Perez-Ramos J, de Lourdes Segura-Valdez M, Vanda B, et al. Matrix metalloproteinases 2, 9, and 13, and tissue inhibitors of metalloproteinases 1 and 2 in experimental lung silicosis. Am J Respir Crit Care Med 1999; 160: 1274-1282. (Pubitemid 29487471)
43. Suga M, Iyonaga K, Okamoto T, et al. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2000; 162: 1949-1956.
44. Choi KH, Lee HB, Jeong MY, et al. The role of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in cryptogenic organizing pneumonia. Chest 2002; 121: 1478-1485. (Pubitemid 34499659)
45. Betsuyaku T, Fukuda Y, Parks WC, et al. Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin. Am J Pathol 2000; 157: 525-535. (Pubitemid 30626912)
46. Cabrera S, Gaxiola M, Arreola JL, et al. Overexpression of MMP9 in macrophages attenuates pulmonary fibrosis induced by bleomycin. Int J Biochem Cell Biol 2007; 39: 2324-2338. (Pubitemid 47484286)
47. Matute-Bello G, Wurfel MM, Lee JS, et al. Essential role of MMP-12 in Fas-induced lung fibrosis. Am J Respir Cell Mol Biol 2007; 37: 210-221. (Pubitemid 47255004)
48. Thickett DR, Perkins GD, O'Kane C, et al. Does MMP-12 play a role in human lung fibrosis? Am J Respir Cell Mol Biol 2008; 38: 247. (Pubitemid 351162847)
49. Tan RJ, Fattman CL, Niehouse LM, et al. Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced lung injury in mice. Am J Respir Cell Mol Biol 2006; 35: 289-297. (Pubitemid 44353396)
50. Flechsig P, Hartenstein B, Teurich S, et al. Loss of matrix metalloproteinase-13 attenuates murine radiation-induced pulmonary fibrosis. Int J Radiat Oncol Biol Phys 2010; 77: 582-590.
51. Garcia-Alvarez J, Ramirez R, Sampieri CL, et al. Membrane typematrix metalloproteinases in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 13-21. (Pubitemid 44259205)
52. Illman SA, Lehti K, Keski-Oja J, et al. Epilysin (MMP-28) induces TGF-β mediated epithelial to mesenchymal transition in lung carcinoma cells. J Cell Sci 2006; 119: 3856-3865. (Pubitemid 44614437)
53. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
54. Di Sario A, Bendia E, Macarri G, et al. The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen α1(I), TIMP-1 and MMP-2. Dig Liver Dis 2004; 36: 744-751. (Pubitemid 41070596)
55. Corbel M, Lanchou J, Germain N, et al. Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice. Eur J Pharmacol 2001; 426: 113-121. (Pubitemid 32781796)
56. Tian XL, Yao W, Guo ZJ, et al. Low dose pirfenidone suppresses transforming growth factor β-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina. Chin Med Sci J 2006; 21: 145-151. (Pubitemid 44637968)
57. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008; 5: e93.
58. Huang YH, Li Y, Shang Y, et al. [Inhibition of pulmonary fibrosis by doxycycline: an experiment with mice]. Zhonghua Yi Xue Za Zhi 2006; 86: 182-186.
59. Fujita M, Ye Q, Ouchi H, et al. Doxycycline attenuated pulmonary fibrosis induced by bleomycin in mice. Antimicrob Agents Chemother 2006; 50: 739-743. (Pubitemid 43190990)
60. Bhattacharyya P, Nag S, Bardhan S, et al. The role of long-term doxycycline in patients of idiopathic pulmonary fibrosis: the results of an open prospective trial. Lung India 2009; 26: 81-85.
61. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294: L152-L160. (Pubitemid 351253350)